American Association for Cancer Research
10780432ccr160496-sup-162551_2_supp_3624040_wbssf2.pdf (1.12 MB)

Supplemental Table 1-4 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma

Download (1.12 MB)
journal contribution
posted on 2023-03-31, 20:04 authored by Jennifer Hansson, David Lindgren, Helén Nilsson, Elinn Johansson, Martin Johansson, Lena Gustavsson, Håkan Axelson

Table S1. Pathological assessment of all the primary tumors used in this paper. pT-grade = pathological tumor grade. Table S2. A list containing all TCGA samples uuids for which mRNA sequencing data was used. Table S3. Comprehensive list of all SLC and ABC transporters that were used in this study. Table S4. Results from the Limma analysis of 442 transporter genes when comparing TCGA gene expression data from 530 ccRCCs against 70 normal kidney samples.



Purpose: Renal cell carcinoma (RCC) is derived from a tissue with a remarkable capacity for vectorial transport. We therefore performed an unbiased exploration of transporter proteins in normal kidney and kidney cancer to discover novel clinical targets.Experimental Design: Using The Cancer Genome Atlas (TCGA) database, we investigated differences in membrane transporter expression in clear cell RCC (ccRCC) and normal kidney. We identified the dopamine transporter SLC6A3 as a specific biomarker for ccRCC. To investigate the functionality of SLC6A3, we used a [3H]-dopamine uptake assay on ccRCC cells. We further explored the effect of hypoxia-inducible factor (HIF) proteins on SLC6A3 expression by introducing siRNA in ccRCC cells and by hypoxic treatment of nonmalignant cells.Results: We show that ccRCC expresses very high transcript levels of SLC6A3 in contrast to normal kidney tissue and other tumor types, which do not express appreciable levels of this transporter. Importantly, we demonstrate that the elevated expression of SLC6A3 in ccRCC cells is associated with specific uptake of dopamine. By targeting the expression of HIF-1α and HIF-2α, we could show that SLC6A3 expression is primarily influenced by HIF-2α and that hypoxia can induce SLC6A3 expression in normal renal cells.Conclusions: We conclude that the dopamine transporter SLC6A3 constitutes a novel biomarker that is highly specific for ccRCC. We further postulate that the protein can be exploited for diagnostic or therapeutic purposes for detection or treatment of ccRCC. Clin Cancer Res; 23(8); 2105–15. ©2016 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager